Cat. No. | Product name | CAS No. |
DC66933 | RG7992 Featured | |
DC66934 |
Fianlimab
Featured
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. |
2126132-98-5 |
DC66935 |
Favezelimab
Featured
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902). |
2231068-83-8 |
DC66936 |
Ieramilimab
Featured
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. |
|
DC66937 |
Encelimab
Featured
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft). |
2173096-82-5 |
DC66938 |
Relatlimab
Featured
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer. |
1673516-98-7 |
DC66939 |
Miptenalimab
Featured
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II. |
2249882-55-9 |
DC66940 | SAR428926 Featured | |
DC66941 | Brigham and Womens anti-LAP Featured | |
DC66942 | Mibavademab Featured | |
DC66943 | MB-311 Featured | |
DC66944 | Anti-LIF Antibody (MSC-1) Featured | |
DC66946 |
Patulin
Featured
Patulin (Terinin) is a mycotoxin produced by fungi including the Aspergillus, Penicillium, and Byssochlamys species, causes chromosome breakage, mutation, teratogenic and cytotoxic. Patulin induces autophagy-dependent apoptosis through lysosomal-mitochondrial axis, and causes DNA damage. |
149-29-1 |
DC66945 |
Polzastobart
Featured
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor. |
2640981-19-5 |
DC66947 | Merck patent anti-ILT3 complex Featured | |
DC66948 | U.Texas patent anti-LILRB4 Featured | |
DC66949 |
Opicinumab
Featured
Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis. |
1422268-07-2 |
DC66950 |
Ladiratuzumab
Featured
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer. |
1629760-28-6 |
DC66951 |
Aflatoxin M2
Featured
Aflatoxin M2 is a major metabolite of Aflatoxin B1. Aflatoxin M2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus. The level of toxicity associated with Aflatoxin is Aflatoxin B1>Aflatoxin M1>Aflatoxin G1>Aflatoxin B2>Aflatoxin M2>Aflatoxin G2. |
6885-57-0 |
DC66952 |
Simtuzumab
Featured
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC). |
1318075-13-6 |
DC66953 | RG7841 Featured | |
DC66954 | Anti-LY75/CD205 Antibody (MEN1309) Featured |